{"id":"https://openalex.org/W2016485702","doi":"https://doi.org/10.1111/j.1365-2125.2006.02696.x","title":"Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects","display_name":"Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects","publication_year":2006,"publication_date":"2006-11-15","ids":{"openalex":"https://openalex.org/W2016485702","doi":"https://doi.org/10.1111/j.1365-2125.2006.02696.x","mag":"2016485702","pmid":"https://pubmed.ncbi.nlm.nih.gov/17118124","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/1885182"},"language":"en","primary_location":{"id":"doi:10.1111/j.1365-2125.2006.02696.x","doi":"https://doi.org/10.1111/j.1365-2125.2006.02696.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.2006.02696.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.2006.02696.x","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.2006.02696.x","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5002715359","display_name":"Sujata Vaidyanathan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Sujata Vaidyanathan","raw_affiliation_strings":["Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. sujata.vaidyanathan@novartis.com","Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. sujata.vaidyanathan@novartis.com","institution_ids":[]},{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA and","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085276906","display_name":"Joanne Jermany","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joanne Jermany","raw_affiliation_strings":["Novartis Institutes for Biomedical Research, Inc., Cambridge, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Institutes for Biomedical Research, Inc., Cambridge, MA, USA,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109217074","display_name":"Ching\u2010Ming Yeh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"ChingMing Yeh","raw_affiliation_strings":["Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA and","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111599832","display_name":"Marie\u2010No\u00eblle Bizot","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210092929","display_name":"Novartis (France)","ror":"https://ror.org/00geypp27","country_code":"FR","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210092929"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Marie\u2010Noelle Bizot","raw_affiliation_strings":["Novartis Pharma SAS, Rueil-Malmaison, France; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma SAS, Rueil-Malmaison, France; and","institution_ids":["https://openalex.org/I4210092929"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5063682985","display_name":"R. Camisasca","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Riccardo Camisasca","raw_affiliation_strings":["Novartis Pharma AG, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5002715359"],"corresponding_institution_ids":["https://openalex.org/I4210117619"],"apc_list":{"value":4780,"currency":"USD","value_usd":4780},"apc_paid":null,"fwci":7.1962,"has_fulltext":true,"cited_by_count":66,"citation_normalized_percentile":{"value":0.97413031,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"62","issue":"6","first_page":"690","last_page":"698"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.9922000169754028,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.9922000169754028,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11917","display_name":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/aliskiren","display_name":"aliskiren","score":1.0},{"id":"https://openalex.org/keywords/renin-inhibitors","display_name":"renin inhibitors","score":0.8090000152587891},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9210000038146973},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.996999979019165},{"id":"https://openalex.org/keywords/plasma-renin-activity","display_name":"plasma renin activity","score":0.843999981880188},{"id":"https://openalex.org/keywords/plasma-renin-concentration","display_name":"plasma renin concentration","score":0.9919999837875366},{"id":"https://openalex.org/keywords/hypertension","display_name":"hypertension","score":0.4620000123977661},{"id":"https://openalex.org/keywords/ethnic-differences","display_name":"ethnic differences","score":0.7239999771118164},{"id":"https://openalex.org/keywords/oral-administration","display_name":"oral administration","score":0.5019999742507935}],"concepts":[{"id":"https://openalex.org/C2779838083","wikidata":"https://www.wikidata.org/wiki/Q414904","display_name":"Aliskiren","level":4,"score":0.9944562911987305},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8466959595680237},{"id":"https://openalex.org/C2777425892","wikidata":"https://www.wikidata.org/wiki/Q409255","display_name":"Renin inhibitor","level":4,"score":0.7720387578010559},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.7626736164093018},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7124748826026917},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.630974292755127},{"id":"https://openalex.org/C138976137","wikidata":"https://www.wikidata.org/wiki/Q7201790","display_name":"Plasma renin activity","level":4,"score":0.5939099192619324},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.5262830853462219},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5224534273147583},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4867420196533203},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.40550071001052856},{"id":"https://openalex.org/C198710026","wikidata":"https://www.wikidata.org/wiki/Q898218","display_name":"Renin\u2013angiotensin system","level":3,"score":0.402677446603775},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.20447978377342224}],"mesh":[{"descriptor_ui":"D000092502","descriptor_name":"Renin Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000577","descriptor_name":"Amides","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000577","descriptor_name":"Amides","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000577","descriptor_name":"Amides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D001794","descriptor_name":"Blood Pressure","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D005650","descriptor_name":"Fumarates","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D005650","descriptor_name":"Fumarates","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D005650","descriptor_name":"Fumarates","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006973","descriptor_name":"Hypertension","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012083","descriptor_name":"Renin","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D012084","descriptor_name":"Renin-Angiotensin System","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D044465","descriptor_name":"White People","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D044466","descriptor_name":"Asian People","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1111/j.1365-2125.2006.02696.x","doi":"https://doi.org/10.1111/j.1365-2125.2006.02696.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.2006.02696.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.2006.02696.x","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:1885182","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/1885182","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Clin Pharmacol","raw_type":"Text"},{"id":"pmid:17118124","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17118124","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of clinical pharmacology","raw_type":"Clinical Trial"}],"best_oa_location":{"id":"doi:10.1111/j.1365-2125.2006.02696.x","doi":"https://doi.org/10.1111/j.1365-2125.2006.02696.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.2006.02696.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.2006.02696.x","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2016485702.pdf","grobid_xml":"https://content.openalex.org/works/W2016485702.grobid-xml"},"referenced_works_count":24,"referenced_works":["https://openalex.org/W1881361989","https://openalex.org/W1974526318","https://openalex.org/W2009001954","https://openalex.org/W2012757283","https://openalex.org/W2015569360","https://openalex.org/W2017344569","https://openalex.org/W2017600141","https://openalex.org/W2018024340","https://openalex.org/W2041871122","https://openalex.org/W2042873619","https://openalex.org/W2069947800","https://openalex.org/W2085927807","https://openalex.org/W2089804373","https://openalex.org/W2096583106","https://openalex.org/W2107914594","https://openalex.org/W2114346603","https://openalex.org/W2121754021","https://openalex.org/W2122088193","https://openalex.org/W2145461177","https://openalex.org/W2151295696","https://openalex.org/W2164834486","https://openalex.org/W2165886950","https://openalex.org/W2330797711","https://openalex.org/W4299551683"],"related_works":["https://openalex.org/W1984727750","https://openalex.org/W2318419775","https://openalex.org/W2136465695","https://openalex.org/W71275700","https://openalex.org/W1990042304","https://openalex.org/W1989480555","https://openalex.org/W2351331456","https://openalex.org/W2021198354","https://openalex.org/W7042531517","https://openalex.org/W2766445359"],"abstract_inverted_index":{"AIMS:":[0],"Aliskiren":[1,233],"is":[2],"the":[3,15,22,79,155,184],"first":[4],"in":[5,29,99,154,217,253],"a":[6,54,107,214],"new":[7],"class":[8],"of":[9,17,27,59,81,106,110,113,158,208],"orally":[10],"effective":[11],"renin":[12,86,91,244],"inhibitors":[13],"for":[14,78,183],"treatment":[16],"hypertension.":[18],"This":[19],"study":[20],"compared":[21,227],"pharmacokinetic":[23,249],"and":[24,31,41,46,64,89,101,131,162,169,181,193,199,219,224,250,255],"pharmacodynamic":[25,251],"properties":[26,252],"aliskiren":[28,60,66,83,111,159,209,246],"Japanese":[30,45,100,161,192,218,254],"Caucasian":[32,48,102,163,194,220,256],"subjects.":[33,257],"METHODS:":[34],"In":[35],"this":[36],"open-label,":[37],"single-centre,":[38],"parallel-group,":[39],"single-":[40],"multiple-dose":[42],"study,":[43],"19":[44,47],"healthy":[49],"young":[50],"male":[51],"subjects":[52,103,195,221],"received":[53],"single":[55,108,205],"300-mg":[56],"oral":[57,206,243],"dose":[58,109,207],"on":[61,71],"day":[62],"1":[63],"then":[65],"300":[67],"mg":[68],"once":[69],"daily":[70],"days":[72],"4-10.":[73],"Blood":[74],"samples":[75],"were":[76,97,187],"collected":[77],"measurement":[80],"plasma":[82,85,90,156],"concentration,":[84],"concentration":[87],"(PRC)":[88],"activity":[92],"(PRA).":[93],"RESULTS:":[94],"Pharmacokinetic":[95],"parameters":[96],"comparable":[98],"following":[104],"administration":[105],"{ratio":[112],"geometric":[114],"means:":[115],"C(max)":[116,137],"1.12":[117],"[90%":[118,127],"confidence":[119],"interval":[120],"(CI)":[121],"0.88,":[122],"1.43];":[123],"AUC(0-72":[124],"h)":[125],"1.19":[126],"CI":[128,140,146],"1.02,":[129],"1.39]}":[130],"at":[132],"steady":[133,176],"state":[134],"[mean":[135],"ratio:":[136],"1.30":[138],"(90%":[139,145],"1.00,":[141],"1.70);":[142],"AUC(0-tau)":[143],"1.16":[144],"0.95,":[147],"1.41)].":[148],"There":[149],"was":[150,234],"no":[151],"notable":[152],"difference":[153],"half-life":[157],"between":[160,191],"groups":[164],"(29.7":[165],"+/-":[166,171],"10.2":[167],"h":[168],"32.0":[170],"6.6":[172],"h,":[173],"respectively).":[174,203],"At":[175],"state,":[177],"peak":[178],"PRC":[179],"level":[180],"AUC":[182],"concentration-time":[185],"plot":[186],"not":[188],"significantly":[189,210],"different":[190],"(P":[196],"=":[197,201],"0.64":[198],"P":[200,230],"0.80,":[202],"A":[204],"reduced":[211],"PRA":[212],"to":[213],"similar":[215,248],"extent":[216],"(by":[222],"87.5%":[223],"85.7%,":[225],"respectively,":[226],"with":[228],"baseline;":[229],"<":[231],"0.01).":[232],"well":[235],"tolerated":[236],"by":[237],"both":[238],"ethnic":[239],"groups.":[240],"CONCLUSIONS:":[241],"The":[242],"inhibitor":[245],"demonstrated":[247]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}